# Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

> **NCT05065970** · PHASE2 · COMPLETED · sponsor: **HI-Bio, A Biogen Company** · enrollment: 54 (actual)

## Conditions studied

- Immunoglobulin A (IgA) Nephropathy

## Interventions

- **DRUG:** Felzartamab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05065970
- **Lead sponsor:** HI-Bio, A Biogen Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-31
- **Primary completion:** 2023-02-06
- **Final completion:** 2024-05-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065970, "Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05065970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*